Risk factors for bleeding in hepatocellular adenoma

British Journal of Surgery

Volumn 101, Issue 7, 2014, Pages 847-855

  Bieze, M ^a   Phoa, S S K S ^b   Verheij, J ^b   Van Lienden, K P ^a   Van Gulik, T M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Department of Radiology ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BLEEDING; FEMALE; HUMAN; LIVER ADENOMA; LIVER DISEASE; LIVER TUMOR; MALE; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; RISK FACTOR; YOUNG ADULT;

ADENOMA, LIVER CELL; ADULT; CONTRACEPTIVES, ORAL; FEMALE; HEMORRHAGE; HUMANS; LIVER DISEASES; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84900482045     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9493     Document Type: Article

References (17)

1. Dokmak S, Paradis V, Vilgrain V, Sauvanet A, Farges O, Valla D, et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology 2009; 137: 1698-1705.
2. Nagorney DM,. Benign hepatic tumors: focal nodular hyperplasia and hepatocellular adenoma. World J Surg 1995; 19: 13-18.
3. Weimann A, Ringe B, Klempnauer J, Lamesch P, Gratz KF, Prokop M, et al. Benign liver tumors: differential diagnosis and indications for surgery. World J Surg 1997; 21: 983-990.
4. Belghiti J, Pateron D, Panis Y, Vilgrain V, Fléjou JF, Benhamou JP, et al. Resection of presumed benign liver tumours. Br J Surg 1993; 80: 380-383.
5. Terkivatan T, de Wilt JH, de Man RA, van Rijn RR, Zondervan PE, Tilanus HW, et al. Indications and long-term outcome of treatment for benign hepatic tumors: a critical appraisal. Arch Surg 2001; 136: 1033-1038.
6. Foster JH, Berman MM,. The malignant transformation of liver cell adenomas. Arch Surg 1994; 129: 712-717.
7. van Aalten SM, de Man RA, Ijzermans JN, Terkivatan T,. Systematic review of haemorrhage and rupture of hepatocellular adenomas. Br J Surg 2012; 99: 911-916.
8. Baum JK, Bookstein JJ, Holtz F, Klein EW,. Possible association between benign hepatomas and oral contraceptives. Lancet 1973; 2: 926-929.
9. Stoot JH, van der Linden E, Terpstra OT, Schaapherder AF,. Life-saving therapy for haemorrhaging liver adenomas using selective arterial embolization. Br J Surg 2007; 94: 1249-1253.
10. Bieze M, van den Esschert JW, Nio CY, Verheij J, Reitsma JB, Terpstra V, et al. Diagnostic accuracy of MRI in differentiating hepatocellular adenoma from focal nodular hyperplasia: prospective study of the additional value of gadoxetate disodium. AJR Am J Roentgenol 2012; 199: 26-34.
11. Bioulac-Sage P, Laumonier H, Couchy G, Le Bail B, Sa Cunha A, Rullier A, et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology 2009; 50: 481-489.
12. Stoot JH, Coelen RJ, De Jong MC, Dejong CH,. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB (Oxford) 2010; 12: 509-522.
13. Melzack R., The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975; 1: 277-299.
14. Vanderiet K, Adriaensen H, Carton H, Vertommen H,. The McGill Pain Questionnaire constructed for the Dutch language (MPQ-DV). Preliminary data concerning reliability and validity. Pain 1987; 30: 395-408.
15. Han J, van den Heuvel MC, Kusano H, de Jong KP, Gouw AS,. How normal is the liver in which the inflammatory type hepatocellular adenoma develops? Int J Hepatol 2012; 2012: 805621.
16. Bioulac-Sage P, Cubel G, Balabaud C, Zucman-Rossi J,. Revisiting the pathology of resected benign hepatocellular nodules using new immunohistochemical markers. Semin Liver Dis 2011; 31: 91-103.
17. Kapp N, Curtis KM,. Hormonal contraceptive use among women with liver tumors: a systematic review. Contraception 2009; 80: 387-390.